← Leaderboards
Andrew B. Sharabi
University Of California, San Diego
$3,226,792
Attributed
$4,221,288
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,221,288 · 3
By mechanism
R01$3,819,754 · 2
R21$401,534 · 1
Top collaborators
- Joseph A Califano3 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- J. Silvio Gutkind$14,229,551
- Ludmil B Alexandrov$5,574,549
- Tracy M Handel$22,625,305
- Sergei I Grivennikov$7,181,444
- Theresa Guo$470,834
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseImproved OutcomeClinical TrialsTumorImmunotherapyCellsAntigen-Presenting CellsRadiationTumor AntigensAntitumor ResponseCombinatorialNeoplastic CellB-LymphocytesTraffickingInsightImmune ResponseRadiation TherapyHead And Neck Squamous Cell CarcinomaHuman PapillomavirusAnti-Tumor Immune ResponseImmunologicsT-LymphocyteAntigen PresentationTumor Immunity
Grant awards (10)
Optimizing immunoradiotherapy for HNSCC$663,994
R01 · FY2025 · CA
Optimizing immunoradiotherapy for HNSCC$632,764
R01 · FY2024 · CA
Optimizing immunoradiotherapy for HNSCC$692,235
R01 · FY2023 · CA
Role of B-cell mediated anti-tumor antibodies in responses to radiation and immunotherapy in HNSCC$367,469
R01 · FY2023 · DE · contact PI
Role of B-cell mediated anti-tumor antibodies in responses to radiation and immunotherapy in HNSCC$363,793
R01 · FY2022 · DE · contact PI
Investigating Mechanisms of Hyperprogression on Anti-PD-1 Immunotherapy$217,163
R21 · FY2022 · CA · contact PI
Role of B-cell mediated anti-tumor antibodies in responses to radiation and immunotherapy in HNSCC$367,178
R01 · FY2021 · DE · contact PI
Investigating Mechanisms of Hyperprogression on Anti-PD-1 Immunotherapy$184,371
R21 · FY2021 · CA · contact PI
Role of B-cell mediated anti-tumor antibodies in responses to radiation and immunotherapy in HNSCC$366,306
R01 · FY2020 · DE · contact PI
Role of B-cell mediated anti-tumor antibodies in responses to radiation and immunotherapy in HNSCC$366,015
R01 · FY2019 · DE · contact PI